Arvinas, Inc.(ARVN) Stock Research - Grey Stern Research

Arvinas, Inc. (ARVN) Stock Analysis

$8.04 (1.13%)

ARVN Financial Performance


Use the table below to view Arvinas, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q4 - 2024

Metric Value Ranking among Peers
Price $8.04 -
52 Week Low $7.79 -
52 Week High $41.98 -
Market Cap $552.9 Million 7/16
Gross Margin 100% 1/16
Profit Margin -76% 9/16
EBITDA margin -96% 5/16
Q4 - 2024 Revenue $59.2 Million 3/16
Q4 - 2024 Earnings -$45.1 Million 9/16
Q4 - 2024 Free Cash Flow -$84.4 Million 15/16
Trailing 4 Quarters Revenue $263.4 Million 2/16
Trailing 4 Quarters Earnings -$198.9 Million 10/16
Quarterly Earnings Growth 71% 2/16
Annual Earnings Growth 43% 2/16
Quarterly Revenue Growth 237% 5/16
Annual Revenue Growth 334% 5/16
Cash On Hand $100.5 Million 10/16
Short Term Debt $1.8 Million 14/16
Long Term Debt $7.9 Million 14/16

Arvinas, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Arvinas, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 1/16
PS 2.10 13/16
PB 0.98 10/16
PC 5.50 6/16
Liabilities to Equity 0.94 4/16
ROA -0.18 2/16
ROE -0.35 6/16
Current Ratio 2.06 12/16
Quick Ratio 1.96 11/16
Long Term Debt to Equity 0.01 14/16
Debt to Equity 0.02 14/16
Burn Rate 2.19 7/16
Cash to Cap 0.18 11/16
CCR 1.87 3/16
EV to EBITDA -8.16 9/16
EV to Revenue 1.75 13/16

Company Details

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

CEO: Dr. John Houston

Website: https://www.arvinas.com

Address: 5 Science Park New Haven, CONNECTICUT

Exchange: NASDAQ Global Select

Industry: Biotechnology

Arvinas, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Arvinas, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Kura Oncology, Inc. KURA $576.6 Million
Ultragenyx Pharmaceutical Inc. RARE $3.6 Billion
Crinetics Pharmaceuticals, Inc. CRNX $3.2 Billion
Stoke Therapeutics, Inc. STOK $402.9 Million
Revolution Medicines, Inc. RVMD $7.1 Billion
Black Diamond Therapeutics, Inc. BDTX $94.6 Million
Pliant Therapeutics, Inc. PLRX $92.5 Million
Relay Therapeutics, Inc. RLAY $506.9 Million
Nurix Therapeutics, Inc. NRIX $952.4 Million
Shattuck Labs, Inc. STTK $54.4 Million
C4 Therapeutics, Inc. CCCC $130.6 Million
Foghorn Therapeutics Inc. FHTX $215.8 Million
Kymera Therapeutics, Inc. KYMR $2.0 Billion
Monte Rosa Therapeutics, Inc. GLUE $323.5 Million
Century Therapeutics, Inc. IPSC $47.2 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
ARVN Income Statements
Quarter Year Revenue Earnings
Q4 2024 $ 59.2 Million -$45.1 Million
Q3 2024 $ 102.4 Million -$49.2 Million
Q2 2024 $ 76.5 Million -$35.2 Million
Q1 2024 $ 25.3 Million -$69.4 Million
Q4 2023 $ 43.1 Million -$154.8 Million
Q3 2023 $ 34.6 Million -$64.0 Million
Q2 2023 $ 54.5 Million -$66.6 Million
Q1 2023 $ 32.5 Million -$80.8 Million

View All

ARVN Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q4 2024 $100.5 Million $1.1 Billion $9.7 Million $561.7 Million
Q3 2024 $85.2 Million $1.2 Billion $600,000 $586.0 Million
Q2 2024 $160.3 Million $1.3 Billion $2.3 Million $600.2 Million
Q1 2024 $93.5 Million $1.2 Billion $2.8 Million $609.7 Million
Q4 2023 $317.2 Million $1.3 Billion $3.2 Million $660.0 Million
Q3 2023 $113.7 Million $1.1 Billion $4.0 Million $457.2 Million
Q2 2023 $90.6 Million $1.1 Billion $4.5 Million $463.6 Million
Q1 2023 $130.2 Million $1.2 Billion $5.0 Million $511.0 Million

View All

ARVN Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q4 2024 -$84.4 Million -$300,000 $15.3 Million
Q3 2024 -$128.7 Million -$700,000 -$75.1 Million
Q2 2024 $49.6 Million -$700,000 $66.8 Million
Q1 2024 -$97.6 Million -$100,000 -$223.7 Million
Q4 2023 $0 $0 $198.0 Million
Q3 2023 -$85.9 Million -$1.1 Million $23.1 Million
Q2 2023 -$89.3 Million -$600,000 -$39.6 Million
Q1 2023 -$92.3 Million -$1.1 Million $48.9 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions